
Enabling precision medicine

Olink Proteomics at a glance
Olink® develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (“PEA”) technology enables researchers to analyze large numbers of proteins with exceptional data quality and minimal sample consumption. This enables research previously not possible while also lowering costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease.
- Location
- Sweden
- Website
- https://www.olink.com
- Investment theme
- Changing Demographics
- Contact
- tommi.unkuri@summaequity.com
- Year exited
- 2024
- SDG alignments
- 3

Press release
Summa Equity has sold its shares in Olink Holding AB (publ) to Thermo Fisher
July 10th, 2024: We are pleased to share that Summa Equity has sold its shares in Olink Holding AB (publ) (“Olink”) to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in relation to their announced public cash tender offer of USD 26.00 per common share in cash, representing USD 26.00 per American Depositary Share (ADS) in cash.